Oncolytics Biotech Inc Stock Price, News & Analysis

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced its participation in the BIO Investor Forum Digital from October 13-15, 2020. Attendees can access an on-demand corporate overview by CEO Dr. Matt Coffey and schedule one-on-one investor meetings through the event website. The company is developing pelareorep, an immuno-oncolytic virus that targets various cancers by inducing tumor lysis. Pelareorep shows potential synergies with immune checkpoint inhibitors and is preparing for a phase 3 study in metastatic breast cancer.

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced its participation in two investor conferences in September 2020. Dr. Matt Coffey, CEO, will present at the LD Micro 500 Virtual Investor Conference on September 3, 2020, at 4:20 pm ET, followed by a presentation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:00 pm ET. Investors can join these webcasts via the links provided. The company is advancing its cancer treatment, pelareorep, which shows promise in enhancing tumor response.

Oncolytics Biotech Inc. (NASDAQ: ONCY) announces the dosing of the first patient in its phase 2 IRENE study evaluating pelareorep combined with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab for triple-negative breast cancer (TNBC). This study, co-sponsored by the Rutgers Cancer Institute of New Jersey and The Ohio State University, aims to assess safety, efficacy, and biomarkers. With a focus on a poorly served cancer subtype, this trial addresses an urgent need for better treatment options in TNBC.

Oncolytics Biotech has initiated the IRENE study, a phase 2 trial examining the combination of pelareorep and Incyte's anti-PD-1 checkpoint inhibitor, retifanlimab, in treating unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The first patient has been dosed as part of this multi-center study, co-sponsored with Rutgers Cancer Institute and The Ohio State University. The trial aims to assess safety, efficacy, PD-L1 expression changes, and T cell clonality. This innovative approach addresses the urgent need for effective treatments in the aggressive TNBC subtype.

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced its participation in the virtual Canaccord Genuity 40th Annual Growth Conference on August 12, 2020. CFO Kirk Look will present at 8:00 am ET, with a live webcast available here. The Company will also conduct one-on-one investor meetings. Oncolytics is focused on developing pelareorep, an immuno-oncolytic virus for cancer treatment, which shows promise in combination with other therapies. For further updates, visit the Company's website.

Oncolytics Biotech reported its Q2 2020 financial results, highlighting significant clinical progress despite COVID-19 challenges. The company initiated the BRACELET-1 trial and presented promising data at the ESMO meeting, confirming the mechanism of action for its lead product, pelareorep. Financially, Oncolytics had $29.9 million in cash but recorded a net loss of $6.8 million, with a diluted loss per share of $0.17. The firm also established an ATM facility to bolster financial flexibility for ongoing clinical trials.

Oncolytics Biotech (NASDAQ: ONCY) announced a conference call on August 4, 2020, at 4:30 PM ET to discuss its second-quarter financial results. The company is focused on its clinical candidate, pelareorep, which is designed to treat various cancers by inducing tumor lysis and enhancing immune responses. Oncolytics is currently preparing for a phase 3 registration study in metastatic breast cancer. Potential risks include interruptions from COVID-19 affecting operations and clinical trials.

Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced a new phase 2 study, IRENE, to investigate the combination of pelareorep and Incyte's retifanlimab in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Conducted by Rutgers Cancer Institute and Ohio State University, the study aims to evaluate safety, objective response rate, and changes in PD-L1 expression in 25 patients. This trial represents an expansion of Oncolytics' breast cancer program and may pave the way for enhanced treatment options in a challenging indication.

Oncolytics Biotech announced the first patient dosing in the phase 2 BRACELET-1 study for HR+/HER2- metastatic breast cancer, under a co-development agreement with Merck KGaA and Pfizer. The study evaluates combination therapies with pelareorep and aims to validate T cell clonality as a biomarker for treatment response. The prior phase 2 trial showed promising results, indicating a near doubling of overall survival. The study will involve 45 patients and will assess safety, tolerability, and efficacy, with results potentially impacting future cancer treatment protocols.